Oral GLP-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now
Patients on Mounjaros highest dose (15 mg weekly) in trials lost on average around 2022% of their weight over ~72 weeks, with over half of patients losing at least 20%
What are the cardiovascular benefits of GLP-1 agonists
And sadly, this has been shown in more than one study
If your heartburn appeared during dose escalation and is gradually improving, stay the course
There are some data to suggest that insulin resistance also occurs in PD [70], however, this is controversial since systemic insulin resistance is not present in de novo, medication-free PD patients [71], and brain insulin resistance is not present in cognitively normal PD cases [72]